Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie

27-09-2024 | Cervical Cancer | Review Article

Precision matters: the value of PET/CT and PET/MRI in the clinical management of cervical cancer

Authors: Yulin Zou, Sijin Zhu, Yinwu Kong, Chengtao Feng, Ru Wang, Linping Lei, Yaomin Zhao, Li Chang, Long Chen

Published in: Strahlentherapie und Onkologie

Login to get access

Abstract

The incidence of cervical cancer has been increasing recently, becoming an essential factor threatening patients’ health. Positron emission computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging (PET/MRI) are multimodal molecular imaging methods that combine functional imaging (PET) and anatomical imaging (CT) with MRI fusion technology. They play an important role in the clinical management of patients with cervical cancer. Precision radiotherapy refers to the use of advanced intensive modulated radiotherapy (IMRT) to give different doses of radiation to different treatment areas to achieve the purpose of killing tumors and protecting normal tissues to the greatest extent. At present, pelvic target delineation is mostly based on CT and MRI, but these mostly provide anatomical morphological information, which is difficult to show the internal metabolism of tumors. PET/CT and PET/MRI combine information on biological function, metabolism and anatomical structure, thereby more accurately distinguishing the boundaries between tumor and non-tumor tissues and playing a positive guiding role in improving radiotherapy planning (RTP) for cervical cancer and evaluating treatment effect.
Literature
1.
Arbyn M et al (2020) Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 8(2):e191–e203PubMedCrossRef
2.
3.
Wright JD et al (2019) Prognostic performance of the 2018 International Federation of Gynecology and Obstetrics cervical cancer staging guidelines. Obstet Gynecol Clin North Am 134(1):49
4.
5.
Romei C et al (2021) New updates of the imaging role in diagnosis, staging, and response treatment of malignant pleural mesothelioma. Cancers 13(17):4377PubMedCrossRefPubMedCentral
6.
Rickard BP et al (2021) Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response. Cancers 13(17):4318PubMedCrossRefPubMedCentral
7.
Xie Y et al (2021) Automated clinical target volume delineation using deep 3D neural networks in radiation therapy of Non-small Cell Lung Cancer. Phys Imaging Radiat Oncol 19: p:131–137CrossRef
8.
9.
Jarrett AM et al (2018) Mathematical models of tumor cell proliferation: A review of the literature. Expert Rev Anticancer Ther 18(12):1271–1286PubMedCrossRefPubMedCentral
10.
Chong LM et al (2021) Recent advances in radiation therapy and photodynamic therapy. Appl Phys Rev 8(4)
11.
Abrantes AM et al (2020) Tumour functional imaging by PET. Biochimica Et Biophys Acta (bba)-molecular Basis Dis 1866(6):165717CrossRef
12.
Cohen-Jonathan-Moyal É et al (2020) Radioresistant tumours: From identification to targeting. Cancer/Radiotherapie 24(6–7):699–705PubMedCrossRef
13.
Nestle U et al (2020) Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol 21(4):581–592PubMedCrossRef
14.
Specht L, Berthelsen AK (2018) PET/CT in radiation therapy planning. in Seminars in nuclear medicine. Elsevier
15.
Alongi P et al (2019) Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 1. Crit Rev Oncol Hematol 140:74–79PubMedCrossRef
16.
Fonti R, Conson M, Del Vecchio S (2019) PET/CT in radiation oncology. in Seminars in oncology. Elsevier
17.
Lohmann P et al (2020) PET/MRI radiomics in patients with brain metastases. Front Neurol 11: p:1CrossRef
18.
Sarabhai T et al (2018) Simultaneous multiparametric PET/MRI for the assessment of therapeutic response to chemotherapy or concurrent chemoradiotherapy of cervical cancer patients: preliminary results. Clin Imaging 49: p:163–168CrossRef
19.
Nguyen NC et al (2020) Diagnostic value of FDG PET/MRI in females with pelvic malignancy—a systematic review of the literature. Front Oncol 10: p:519440CrossRef
20.
Sarabhai T et al (2018) Comparison of 18 F-FDG PET/MRI and MRI for pre-therapeutic tumor staging of patients with primary cancer of the uterine cervix. Eur J Nucl Med Mol Imaging 45:67–76PubMedCrossRef
21.
Nawapun S et al (2021) Correlation of clinical staging and MRI staging for cervical cancer. Egypt J Radiol Nucl Med 52:1–7CrossRef
22.
Steiner A et al (2021) Diagnostic efficiency of whole-body 18F-FDG PET/MRI, MRI alone, and SUV and ADC values in staging of primary uterine cervical cancer. Cancer Imaging 21(1):1–11CrossRef
23.
Martinez A et al (2020) Tumour and pelvic lymph node metabolic activity on FDG-PET/CT to stratify patients for para-aortic surgical staging in locally advanced cervical cancer. Eur J Nucl Med Mol Imaging 47:1252–1260PubMedCrossRef
24.
Cegla P et al (2019) Influence of 18F-FDG-PET/CT on staging of cervical cancer. Nuklearmedizin-NuclearMedicine 58(01):17–22CrossRef
25.
Nguyen NC et al (2020) 18F-FDG PET/MRI primary staging of cervical cancer: a pilot study with PET/CT comparison. J Nucl Med Technol 48(4):331–335PubMedCrossRef
26.
27.
Tsuyoshi H et al (2021) Diagnostic value of 18F-FDG PET/MRI for revised 2018 FIGO staging in patients with cervical cancer. Diagnostics 11(2):202PubMedCrossRefPubMedCentral
28.
Wegen S et al (2023) First clinical experience with [68Ga] Ga-FAPI-46-PET/CT versus [18F] F‑FDG PET/CT for nodal staging in cervical cancer. Clin Nucl Med 48(2):150PubMedCrossRef
29.
Wong TZ, Jones EL, Coleman RE (2004) Positron emission tomography with 2‑deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. Mol Imaging Biol 6(1):55–62PubMedCrossRef
30.
Chou HH et al (2006) Low value of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in primary staging of early-stage cervical cancer before radical hysterectomy. J Clin Oncol 24(1):123–128PubMedCrossRef
31.
Kidd EA et al (2009) Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. Cancer 115(15):3548–3554PubMedCrossRef
32.
Otani T et al (2023) Prognostic value of pretreatment FDG PET/CT in uterine cervical cancer according to two major histologic types: squamous cell carcinoma and adenocarcinoma. Asia Ocean J Nucl Med Biol 11(2):101PubMedPubMedCentral
33.
McComas KN et al (2020) The variable impact of positive lymph nodes in cervical cancer: Implications of the new FIGO staging system. Gynecol Oncol 156(1):85–92PubMedCrossRef
34.
Widschwendter P et al (2019) Prognostic factors for and pattern of lymph-node involvement in patients with operable cervical cancer. Arch Gynecol Obstet 300: p:1709–1718CrossRef
35.
Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424PubMedCrossRef
36.
37.
Holtkamp LH et al (2020) Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases. Melanoma Res 30(4):358PubMedCrossRefPubMedCentral
38.
Ohno Y et al (2023) Computed DWI MRI Results in Superior Capability for N‑Stage Assessment of Non-Small Cell Lung Cancer Than That of Actual DWI, STIR Imaging, and FDG-PET/CT. J Magn Reson Imaging 57(1):259–272PubMedCrossRef
39.
Mansoori B et al (2020) Multimodality Imaging of Uterine Cervical Malignancies. AJR Am J Roentgenol 215(2):292–304PubMedCrossRef
40.
Goense L et al (2018) Limited additional value of cervical ultrasonography over a negative 18F-FDG PET/CT for diagnosing cervical lymph node metastases in patients with esophageal cancer: a systematic review and meta-analysis. Nucl Med Commun 39(7): p:645–651CrossRef
41.
Zhang L et al (2018) Evaluation of 18F-FDG PET/CT parameters for reflection of aggressiveness and prediction of prognosis in early-stage cervical cancer. Nucl Med Commun 39(11):1045–1052PubMedCrossRef
42.
43.
Madsen K et al (2019) Diagnostic PET/CT for detecting malignant lymph nodes in patients with cervical cancer Stage IB1. EJGO 40(6):953–957CrossRef
44.
Tanaka T et al (2018) Which is better for predicting pelvic lymph node metastases in patients with cervical cancer: Fluorodeoxyglucose-positron emission tomography/computed tomography or a sentinel node biopsy? A retrospective observational study. Medicine 97(e0410):16
45.
Anner P et al (2018) (18)F]FDG-PET/CT and MRI for initial pelvic lymph node staging in patients with cervical carcinoma: The potential usefulness of [(18)F]FDG-PET/MRI. Oncol Lett 15(3):3951–3956PubMedPubMedCentral
46.
Havrilesky LJ et al (2005) FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 97(1):183–191PubMedCrossRef
47.
De Cuypere M et al (2020) Added value of Para-aortic surgical staging compared to 18F-FDG PET/CT on the external beam radiation field for patients with locally advanced cervical cancer: an ONCO-GF study. Eur J Surg Oncol 46(5):883–887PubMedCrossRef
48.
Tsuyoshi H et al (2020) Diagnostic value of 18F-FDG PET/MRI for staging in patients with endometrial cancer. Cancer Imaging 20(1):1–9CrossRef
49.
Zhu Y et al (2021) CT, MRI, and PET imaging features in cervical cancer staging and lymph node metastasis. Am J Transl Res 13(9):10536PubMedPubMedCentral
50.
Sugawara Y et al (1999) Evaluation of FDG PET in patients with cervical cancer. J Nucl Med 40(7):1125–1131PubMed
51.
Rose PG et al (1999) Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 17(1):41–45PubMedCrossRef
52.
Verma V et al (2018) Use of PET and Other Functional Imaging to Guide Target Delineation in Radiation Oncology. Semin Radiat Oncol 28(3):171–177PubMedCrossRef
53.
Fiorentino A et al (2019) Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2. Crit Rev Oncol Hematol 139:117–124PubMedCrossRef
54.
55.
Gouy S et al (2021) False negative rate at 18F-FDG PET/CT in para-aortic lymphnode involvement in patients with locally advanced cervical cancer: impact of PET technology. BMC Cancer 21(1):1–9CrossRef
56.
Esthappan J et al (2004) Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes. Int J Radiat Oncol Biol Phys 58(4):1289–1297PubMedCrossRef
57.
58.
Nam H et al (2012) 18F-fluorodeoxyglucose positron emisson tomography/computed tomography guided conformal brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 84(1):e29–34PubMedCrossRef
59.
Haynes-Outlaw ED, Grigsby PW (2010) The Role of FDG-PET/CT in Cervical Cancer: Diagnosis, Staging, Radiation Treatment Planning and Follow-Up. PET Clin 5(4):435–446PubMedCrossRef
60.
Mayadev J et al (2022) Durvalumab in Combination with Chemoradiotherapy (CRT) in Locally Advanced Cervical Cancer (LACC): Radiotherapy (RT) Delivery and Subgroup Analyses from CALLA. Int J Radiat Oncol Biol Phys 114(5):1058–1059CrossRef
61.
Corbeau A et al (2021) Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic review. Radiother Oncol 164:128–137PubMedCrossRef
62.
Zhou YM et al (2018) The absolute volume of PET-defined, active bone marrow spared predicts for high grade hematologic toxicity in cervical cancer patients undergoing chemoradiation. Clin Transl Oncol 20(6):713–718PubMedCrossRef
63.
McGuire SM et al (2016) Using [(18)F]Fluorothymidine Imaged With Positron Emission Tomography to Quantify and Reduce Hematologic Toxicity Due to Chemoradiation Therapy for Pelvic Cancer Patients. Int J Radiat Oncol Biol Phys 96(1):228–239PubMedCrossRefPubMedCentral
64.
Su T‑P et al (2018) Comparison of positron emission tomography/computed tomography and magnetic resonance imaging for posttherapy evaluation in patients with advanced cervical cancer receiving definitive concurrent chemoradiotherapy. Eur J Nucl Med Mol Imaging 45: p:727–734CrossRef
65.
Lou Y et al (2023) The prognostic value of the ratio of standard uptake value of lymph node to primary tumor before treatment of locally advanced nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol 280(1):347–356PubMedCrossRef
66.
Shou H et al (2021) Association of pretreatment SUVmax of cervix and SCC-antigen with FIGO2018 stage in Stage IIB-IVB squamous cervical cancer and relationship to prognosis. Intl J Gynecology & Obste 152(1):112–117CrossRef
67.
Kidd EA et al (2013) Changes in cervical cancer FDG uptake during chemoradiation and association with response. Int J Radiat Oncol Biol Phys 85(1):116–122PubMedCrossRef
68.
Catana C, Guimaraes AR, Rosen BR (2013) PET and MR imaging: the odd couple or a match made in heaven? J Nucl Med 54(5):815–824PubMedCrossRef
69.
70.
71.
Cheng Y et al (2020) Preliminary clinical results for PET/MR compared with PET/CT in patients with nasopharyngeal carcinoma. Oncol Rep 43(1):177–187PubMed
72.
Gong J et al (2021) Relative clinical utility of simultaneous (18)F-fluorodeoxyglucose PET/MRI and PET/CT for preoperative cervical cancer diagnosis. J Int Med Res 49(6):3000605211019190PubMedCrossRef
73.
Xin J et al (2016) PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer. Eur J Radiol 85(4):751–759PubMedCrossRef
74.
Grueneisen J et al (2015) Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results. Eur J Nucl Med Mol Imaging 42(12):1814–1824PubMedCrossRef
75.
Xu C et al (2020) Value of integrated PET-IVIM MR in assessing metastases in hypermetabolic pelvic lymph nodes in cervical cancer: a multi-parameter study. Eur Radiol 30: p:2483–2492CrossRef
76.
Schwartz M et al (2018) Feasibility and diagnostic performance of hybrid PET/MRI compared with PET/CT for gynecological malignancies: a prospective pilot study. Abdom Radiol 43(12):3462–3467CrossRef
77.
Kim SK et al (2009) Additional value of MR/PET fusion compared with PET/CT in the detection of lymph node metastases in cervical cancer patients. Eur J Cancer 45(12):2103–2109PubMedCrossRef
78.
Kitajima K et al (2014) Fusion of PET and MRI for staging of uterine cervical cancer: comparison with contrast-enhanced (18)F-FDG PET/CT and pelvic MRI. Clin Imaging 38(4):464–469PubMedCrossRef
79.
Chan S‑C et al (2018) Clinical utility of simultaneous whole-body 18 F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 45:1297–1308PubMedCrossRef
80.
Ahangari S et al (2021) Toward PET/MRI as one-stop shop for radiotherapy planning in cervical cancer patients. Acta Oncol 60(8):1045–1053PubMedCrossRef
81.
Zhang S et al (2014) Comparison of tumor volume between PET and MRI in cervical cancer with hybrid PET/MR. Int J Gynecol Cancer 24(4):744–750PubMedCrossRef
82.
Sun H et al (2014) Anatomical and functional volume concordance between FDG PET, and T2 and diffusion-weighted MRI for cervical cancer: a hybrid PET/MR study. Eur J Nucl Med Mol Imaging 41(5):898–905PubMedCrossRef
83.
Kidd EA et al (2010) Pelvic lymph node F‑18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer 116(6):1469–1475PubMedCrossRef
84.
Vojtíšek R et al (2021) Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy. Strahlenther Onkol 197(6):494–504PubMedCrossRef
85.
Xu C et al (2019) Early treatment response of patients undergoing concurrent chemoradiotherapy for cervical cancer: An evaluation of integrated multi-parameter PET-IVIM MR. Eur J Radiol 117:1–8PubMedCrossRef
86.
Gao S et al (2020) Multiparametric PET/MR (PET and MR-IVIM) for the evaluation of early treatment response and prediction of tumor recurrence in patients with locally advanced cervical cancer. Eur Radiol 30(2):1191–1201PubMedCrossRef
87.
Richard SD et al (2011) Noninvasive assessment of cell proliferation in ovarian cancer using [18F] 3’deoxy-3-fluorothymidine positron emission tomography/computed tomography imaging. Nucl Med Biol 38(4):485–491PubMedCrossRef
88.
Dehdashti F et al (2003) Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response—a preliminary report. Int J Radiat Oncol Biol Phys 55(5):1233–1238PubMedCrossRef
89.
Dehdashti F et al (2008) Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 49(2):201–205PubMedCrossRef
90.
Davis AT et al (2018) Assessment of the variation in CT scanner performance (image quality and Hounsfield units) with scan parameters, for image optimisation in radiotherapy treatment planning. Phys Med 45:59–64PubMedCrossRef
91.
Otazo R et al (2021) MRI-guided Radiation Therapy: An Emerging Paradigm in Adaptive Radiation Oncology. Radiology 298(2):248–260PubMedCrossRef
Metadata
Title
Precision matters: the value of PET/CT and PET/MRI in the clinical management of cervical cancer
Authors
Yulin Zou
Sijin Zhu
Yinwu Kong
Chengtao Feng
Ru Wang
Linping Lei
Yaomin Zhao
Li Chang
Long Chen
Publication date
27-09-2024
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-024-02294-8